NCT04249622 2025-09-16
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Phase 2 Terminated
Clinical Trials
5 trialsNCT03820817 2025-04-20
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
Phase 1 Active not recruiting
NCT06783153 2025-01-20
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
Phase 1/2 Not yet recruiting
NCT05502913 2023-10-02
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
Soroka University Medical Center
Phase 2 Recruiting
NCT00967096 2013-11-27
Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)
Emory University
Phase 1 Completed